CDKN2A and colon adenocarcinoma: However, the OS in COAD patients has been poorly diagnosed due to the lack of biomarkers that assist in early medical decisions, suggesting a therapeutic plan or approach, as the CDKN2A gene has proven its capability to be a potential prognostic biomarker, as one of the studies has done so in the form of identifying new prognostic signatures in COAD [22] and validating its malignancy in serum, resulting in even understanding the high toxicity instability of COAD [23] and investigating the overall survival in association with gene expression [24].